Deputy Minister of Economic Development visited Pharmasyntez-Nord

31.10.2022

Dmitry Vakhrukov paid a working visit to the Novoorlovskaya facility of the Special Economic Zone of Saint Petersburg, where the largest pharmaceutical cluster is presented, the total volume of investments of its residents, producing medicines, is more than 62 billion rubles. Among them is Pharmasyntez-Nord JSC, the largest research and manufacturing complex of the Pharmasyntez Group of Companies, which produces anti-tumor drugs as part of the import substitution program.

The Deputy Minister inspected the second production line of Pharmasyntez-Nord.

“Currently the production lines of the complex undergo stage-by-stage licensing procedure, which is planned to be completed by the end of 2022. Industrial launch of the production complex with the area of more than 30 thousand sq. m. is planned for the first quarter of 2023. The new site will be specialized in production of biotechnological drugs for the treatment of diabetes mellitus, rheumatoid arthritis, oncological diseases, and prevention of the new coronavirus infection Covid-19,” Mikhail Kvasnikov, Chief Executive Officer of Pharmasyntez-Nord JSC, told.

The company has 776 employees, and this number will increase to 1,100 once the new manufacturing site reaches its project capacity. The amount of committed investments for the development of production capacity of Pharmasyntez-Nord is 13.8 billion rubles, of which 8.1 billion rubles have already been invested.

“The new projects in the Special Economic Zone of Saint Petersburg are an example of implementation of strategic priorities indicated by the country’s senior executives in terms of ensuring technological sovereignty in key industries, pharmaceutics and petrochemistry. We can see in practice how technological niches vacated by unfriendly countries are being filled with high-tech domestic products. The Special Economic Zone mode contributes to the intensity of these processes,” Dmitry Vakhrukov noted.

“The St. Petersburg Special Economic Zone is known for its powerful pharmaceutical cluster. Cooperation between pharmaceutical companies-residents of the Special Economic Zone and the developer of technologies for the production of components from petrochemicals will give an excellent synergy effect and impetus to the production of pharmaceutical substances with the shortage observed,” Tamara Rondaleva, Chief Executive Officer of St. Petersburg Special Economic Zone, commented.